Get In On This Crisis Investment While You Can
The headline screamed "Amazon, Google and Netflix are fighting over this rare gas," which is helium, nonrenewable, and running out. When it's gone it's gone. That's a huge crisis for medicine, the military, and computer chips that run the 21st century's gadgets, appliances, and vehicles. But, a couple small companies have a solution.
Get a free report that shows you the crisis
Brian M. Silver, insider at Tscan Therapeutics
Brian M. Silver Insider Alerts

Get notified the next time Brian M. Silver buys or sells Tscan Therapeutics stock. Enter your email address below to get our daily insider buying and selling report.

Brian M. Silver Insider Information

Brian Silver is the Chief Financial Officer at TScan Therapeutics. Prior to joining TScan, Brian served as Freeline Therapeutics’ CFO and Head of Corporate Development, overseeing the Company’s financial, corporate legal and business development operations, including corporate strategy, BD&L, legal and compliance, investor relations, accounting, financial planning and analysis, IT, tax and treasury. In just over two years at Freeline, Brian raised over $300 million in capital, via a crossover financing as well as in one of the largest ever Nasdaq IPOs for a UK-based clinical-stage biotech company.

Before joining Freeline, Brian was Partner and Head of Biotechnology in the healthcare practice at Perella Weinberg Partners, a leading independent global advisory firm. Prior to that, Brian was a Managing Director in Morgan Stanley’s healthcare investment banking group and a corporate associate at Sullivan & Cromwell.

Brian has worked with a range of large and emerging pharmaceutical and biotechnology clients during his 25-year Wall Street career. His investment banking and corporate law advisory experience includes dozens of M&A and financing transactions across all capital markets, including IPOs, follow-ons, high yield and investment grade debt, and royalty financings. His M&A experience includes sell side and buy side transactions and leveraged buyouts, as well as reverse mergers and corporate restructurings.

Brian received a BA with honors from Harvard College and a JD with honors from the University of Chicago Law School.

How do I contact Brian M. Silver?

The corporate mailing address for Mr. Silver and other Tscan Therapeutics executives is 830 WINTER STREET, WALTHAM MA, 02451. Tscan Therapeutics can also be reached via email at [email protected]

Has Brian M. Silver been buying or selling shares of Tscan Therapeutics?

Brian M. Silver has not been actively trading shares of Tscan Therapeutics during the last ninety days. Most recently, on Tuesday, September 21st, Brian M. Silver bought 5,000 shares of Tscan Therapeutics stock. The stock was acquired at an average cost of $6.32 per share, with a total value of $31,600.00.

Who are Tscan Therapeutics' active insiders?

Tscan Therapeutics' insider roster includes Gavin MacBeath (Insider), Brian Silver (CFO), and Zoran Zdraveski (Insider).

Are insiders buying or selling shares of Tscan Therapeutics?

In the last year, Tscan Therapeutics insiders bought shares 3 times. They purchased a total of 14,659 shares worth more than $97,621.14. The most recent insider tranaction occured on September, 23rd when insider Zoran Zdraveski bought 4,716 shares worth more than $35,275.68.

Information on this page was last updated on 9/23/2021.

Brian M. Silver Insider Trading History at Tscan Therapeutics

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/21/2021Buy5,000$6.32$31,600.00View SEC Filing Icon  
See Full Table

Brian M. Silver Buying and Selling Activity at Tscan Therapeutics

This chart shows Brian M Silver's buying and selling at Tscan Therapeutics by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Tscan Therapeutics Company Overview

Tscan Therapeutics logo
TScan Therapeutics Inc. is a biopharmaceutical company. It focused on the development of T-cell receptor engineered T cell therapies for the treatment of patients with cancer. The company's lead product pipeline consist TSC-100 and TSC-101. TScan Therapeutics Inc. is based in WALTHAM, Mass.
Read More

Today's Range

Now: $7.92
Low: $7.90
High: $8.79

50 Day Range

MA: $8.04
Low: $6.17
High: $9.05

2 Week Range

Now: $7.92
Low: $6.06
High: $14.71

Volume

14,632 shs

Average Volume

72,071 shs

Market Capitalization

$188.24 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A
Biden Executive Order 14017 Potentially Sending Lithium Stocks Skyrocketing
The White House is scared of our country's lithium supply running out. That's why Biden issued executive order 14017 to figure out how to expand our lithium production. And this is GREAT news for one company who's gobbling up land in the lithium-rich Nevada desert.
Exec-Order 14017 Could Send This Company Skyrocket